LPCN · Lipocine Inc
United States · RS rating 7 · As of 2026-10-14
| Price | 1.69 USD |
|---|---|
| 1-day change | +4.3% |
| RS rating (overall / 1M / 3M / 12M) | 7 / 10 / 14 / 15 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 34 / 13 / 36 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +40.7% |
| Sales growth Q/Q | +899.7% |
| Distance from 52-week high | +85.0% |
| Market cap (USD) | $18.9M |